OPEN ACCESS Freely available online

ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics

Short Communication

Advancements in RNA Therapeutics: Targeting Genetic Disorders at the Molecular Level

Meroni Munro*

Department of Biological Sciences, Humboldt University, Berlin, Germany

DESCRIPTION

RNA therapeutics has emerged as a potential avenue for treating genetic disorders by targeting the underlying molecular mechanisms of disease. Unlike traditional small molecule drugs, RNA-based therapies offer the potential to modulate gene expression, correct aberrant RNA processing, and restore normal cellular functions. This article explores the recent advancements in RNA therapeutics, including RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and RNA editing technologies, and their applications in targeting genetic disorders at the molecular level [1,2].

Understanding RNA therapeutics

RNA therapeutics encompasses a diverse array of approaches aimed at modulating gene expression and function at the RNA level.

RNA Interference (RNAi): RNAi is a natural cellular process for silencing gene expression by degrading target mRNA molecules. Synthetic small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) can be designed to specifically target and degrade complementary mRNA sequences, thereby inhibiting gene expression.

Antisense Oligonucleotides (ASOs): ASOs are synthetic single-stranded nucleic acid molecules designed to hybridize with target RNA sequences. By binding to specific mRNA targets, ASOs can modulate RNA splicing, promote mRNA degradation, or block translation, depending on the mechanism of action.

RNA Editing Technologies: RNA editing technologies, such as base editing and RNA base modification, enable precise modifications to RNA sequences. These technologies offer the potential to correct disease-causing mutations or introduce specific nucleotide changes into RNA transcripts.

Applications in genetic disorders

RNA therapeutics has potential for treating a wide range of genetic disorders, including:

Neurological disorders: Neurological disorders, such as Spinal Muscular Atrophy (SMA), Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS), are characterized by aberrant RNA processing and dysregulated gene expression. RNA therapeutics targeting disease-associated genes, such as Survival Motor Neuron 1 (*SMN1*) in SMA, have shown promising results in preclinical and clinical studies [3-5].

Neuromuscular disorders: Neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy (DM), are caused by mutations in genes encoding muscle-specific proteins. RNA-based therapies, such as exon skipping and splice modulation, aim to restore normal protein expression and function in affected muscle cells.

Metabolic disorders: Metabolic disorders, such as Familial Hypercholesterolemia (FH) and hereditary transthyretin amyloidosis, result from mutations in genes involved in lipid metabolism or protein folding. RNA therapeutics targeting specific metabolic pathways, such as LDL cholesterol synthesis or transthyretin production, offer potential treatments for these disorders.

Oncological disorders: Oncological disorders, including various cancers and hematological malignancies, are driven by dysregulated gene expression and signaling pathways. RNA-based therapies, such as RNAi-mediated silencing of oncogenes or ASO-mediated inhibition of tumor-promoting proteins, hold promise for cancer treatment and precision oncology [6].

Advancements in RNA therapeutics

Recent advancements in RNA therapeutics have significantly expanded the scope and efficacy of RNA-based treatments. Some key advancements include:

Correspondence to: Meroni Munro, Department of Biological Sciences, Humboldt University, Berlin, Germany, E-mail: m.munro@gmail.com

Received: 01-Apr-2024, Manuscript No. BOM-24-25906; **Editor assigned:** 03-Apr-2024, Pre QC No. BOM-24-25906 (PQ); **Reviewed:** 17-Apr-2024, QC No. BOM-24-25906; **Revised:** 24-Apr-2024, Manuscript No. BOM-24-25906 (R); **Published:** 02-May-2024, DOI: 10.35248/2167-7956.24.13.382

Citation: Munro M (2024) Advancements in RNA Therapeutics: Targeting Genetic Disorders at the Molecular Level. J Biomol Res. 13.382.

Chemical modifications: Chemical modifications to RNA molecules, such as 2'-O-Methyl (2'-OMe) and Locked Nucleic Acid (LNA) modifications, improve stability, enhance binding affinity, and reduce immunogenicity. These modifications enable the development of more potent and durable RNA therapeutics with improved pharmacokinetic properties.

Next-Generation Sequencing (NGS) technologies: NGS technologies enable comprehensive profiling of RNA transcripts and splicing patterns, providing valuable insights into disease mechanisms and therapeutic targets. High-throughput screening approaches using CRISPR-based or RNAi-based libraries facilitate the identification of novel RNA targets for therapeutic intervention.

RNA editing technologies: RNA editing technologies, such as base editing and RNA base modification, offer precise and programmable tools for correcting disease-causing mutations at the RNA level. These technologies having potential for treating a wide range of genetic disorders, including those caused by point mutations or Single Nucleotide Polymorphisms (SNPs) [7].

Challenges and future directions

Despite the significant progress in RNA therapeutics, several challenges and future directions need to be addressed to realize the full potential of RNA-based treatments:

Specificity and off-target effects: Achieving specificity and minimizing off-target effects remain key challenges in RNA therapeutics. Strategies to improve target recognition and reduce off-target binding, such as rational design of ASOs and chemical modifications, are actively being pursued.

Immune response: The immune response to RNA-based therapeutics, particularly ASOs and viral vectors, can limit their efficacy and safety in vivo. Strategies to modulate immune responses and enhance the tolerability of RNA-based treatments are under investigation [8-10].

CONCLUSION

Advancements in RNA therapeutics offer unprecedented opportunities for targeting genetic disorders at the molecular level and addressing unmet medical needs across a wide range of diseases. By leveraging the power of RNA interference, antisense oligonucleotides, RNA editing technologies, and other RNA-based approaches, researchers and clinicians are poised to revolutionize the treatment of genetic disorders and improve patient outcomes in the era of precision medicine. Continued interdisciplinary collaboration, technological innovation, and regulatory support are essential for realizing the full potential of RNA therapeutics and transforming the landscape of genetic medicine.

REFERENCES

1. Thornber K, Pitchforth E. Communicating antimicrobial resistance: The need to go beyond human health. JAC-Antimicrobial Resistance. 2021;3(3):096.
2. Dadgostar P. Antimicrobial resistance: Implications and costs. Infection and drug resistance. 2019; 12:3903.
3. Pandey S. Preliminary phytochemical screening and in vitro antibacterial activity of Bauhinia variegata Linn. Against human pathogens. Asian Pac J Trop Dis. 2015;5(2): 121-129.
4. Kebede T, Gadisa E, Tufa A. Antimicrobial activities evaluation and phytochemical screening of some selected medicinal plants: A possible alternative in the treatment of multidrug-resistant microbes. PLoS One. 2021;16(3):0249253.
5. Valli M, Pivatto M, Danuello A, Castro-Gamboa I, Silva DH, Cavalheiro AJ, et al,. Tropical biodiversity: Has it been a potential source of secondary metabolites useful for medicinal chemistry?. Química Nova. 2012;35:2278-2287.
6. Parvin S, Kader MA, Chouduri AU, Shuaib MA, Rafshanjani M, Haque E. Antibacterial, antifungal and insecticidal activities of the n-hexane and ethyl-acetate fractions of methanolic extract of the leaves of Calotropis gigantea Linn. J Pharmacogn Phytochem. 2014;2(5):47-51.
7. Negi BS, Dave BP, Agarwal YK. Evaluation of antimicrobial activity of Bauhinia purpurea leaves under in vitro conditions. Indian J Microbiol. 2012;52(3):360-365.
8. Azevedo CR, Maciel FM, Silva LB, Ferreira AT, Da Cunha M, Machado OL, et al. Isolation and intracellular localization of insulin-like proteins from leaves of *Bauhinia variegata*. Braz J Med Biol. Res. 2006;39:1435-1444.
9. Gobo LA, Viana C, Lameira OA, de Carvalho LM. A liquid chromatography-atmospheric pressure photoionization tandem mass spectrometric (LC-APPI-MS/MS) method for the determination of triterpenoids in medicinal plant extracts. J Mass Spectrom. 2016;51(8):558-565.
10. Hago S, Mahrous EA, Moawad M, Abdel-Wahab S, Abdel-Sattar E. Evaluation of antidiabetic activity of *Morus nigra* L. and *Bauhinia variegata* L. leaves as Egyptian remedies used for the treatment of diabetes. Nat. Prod. Res. 2021;35(5):829-835.